Business
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout fro
About this update from Skye Bioscience, Inc.
[{"type":"image","alt":"Skye Bioscience, Inc.","displaySize":"","headline":null,"caption":"Skye Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":141,"url":"https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7pwAl2G8ZGCyG39CbcNdmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"In vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonists","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded preclinical study data to be presented at ADA in June 2025","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025","length":94,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":569,"olType":false},{"type":"text","content":"SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2025, along with key accomplishments and upcoming milestones.","length":417,"tagName":"p"},{"type":"text","content":"“In Q1, we made decisive progress across clinical operations and R&D,” said Punit Dhillon, President & CEO of Skye. “Nimacimab continues to demonstrate a differentiated profile as a potential weight loss therapy, with a peripherally restricted mechanism that may set it apart from both GLP-1s and small-molecule CB1 inhibitors. We’re advancing a body of preclinical and clinical evidence that supports its potential in reshaping the tr...